Immunotherapy targeting EBV-expressing lymphoproliferative diseases.
Epstein-Barr virus (EBV) is associated with non-Hodgkin's lymphoma (NHL), occurring in immunocompetent individuals as well as those with immunodeficiency. In patients with immunodeficiency, the nature of EBV infection in the malignant cell determines the pattern of antigen expression and the associated presence of targets for cellular immunotherapy. EBV-expressing lymphoma cells in the setting of immunodeficiency express type III latency, characterized by expression of all nine latent-cycle EBV antigens, and strategies to restore EBV-specific immune responses have resulted in effective anti-tumour activity. In contrast, EBV-associated NHL in immunocompetent individuals is characterized by type II latency, where a more restricted array of EBV-associated antigens is expressed. In this setting, T-cell therapies are limited by inadequate persistence of transferred T cells and by tumour-evasion strategies. A number of strategies to genetically modify the infused T cells and modulate the host environment are under evaluation.
Bollard
Catherine M
CM
Center for Cell and Gene Therapy, Baylor College of Medicine, The Methodist Hospital and Texas Children's Hospital, Houston, TX, USA.
Cooper
Laurence J
LJ
Heslop
Helen E
HE
D000914:Antibodies, Viral / Q000276:immunology / Q000627:therapeutic use; D020031:Epstein-Barr Virus Infections / Q000276:immunology; D004854:Herpesvirus 4, Human / Q000276:immunology*; D006689:Hodgkin Disease / Q000276:immunology / Q000628:therapy; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D017710:Lymphocyte Transfusion; D008223:Lymphoma / Q000276:immunology / Q000628:therapy; D008228:Lymphoma, Non-Hodgkin / Q000276:immunology*; D008232:Lymphoproliferative Disorders / Q000276:immunology*; D013601:T-Lymphocytes / Q000276:immunology; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology; D017735:Virus Latency / Q000276:immunology
D000914:Antibodies, Viral
Nat Biotechnol. 2008 Apr;26(4):453-61
18376399
Am J Transplant. 2007 Jun;7(6):1648-55
17511690
Ann Hematol. 2007 Aug;86(8):599-607
17522862
J Exp Med. 2004 Dec 20;200(12):1623-33
15611290
J Immunother. 2004 Jul-Aug;27(4):317-27
15235393
Nat Rev Cancer. 2004 Oct;4(10):757-68
15510157
Blood. 2007 Oct 15;110(8):2838-45
17609424
J Immunother. 2006 May-Jun;29(3):250-60
16699368
Mol Ther. 2007 Apr;15(4):825-33
17299405
Blood. 2006 Oct 15;108(8):2874-80
16804113
N Engl J Med. 1999 Apr 22;340(16):1239-47
10210707
Eur J Immunol. 2001 Mar;31(3):947-58
11241300
Nat Rev Cancer. 2003 Jan;3(1):35-45
12509765
Cancer Treat Res. 1999;99:27-45
9891862
Mol Ther. 2004 Apr;9(4):577-86
15093188
Nat Med. 2007 Dec;13(12):1440-9
18026115
Science. 2002 Oct 25;298(5594):850-4
12242449
Blood. 2001 Jan 1;97(1):250-5
11133768
Blood. 2000 Feb 1;95(3):807-14
10648390
Blood. 1998 Sep 1;92(5):1549-55
9716582
Immunol Rev. 2008 Feb;221:77-89
18275476
Blood. 2002 Mar 15;99(6):2009-16
11877273
Nat Med. 2003 Mar;9(3):279-86
12579196
Blood. 1999 Oct 1;94(7):2208-16
10498590
J Pathol. 2000 Feb;190(2):143-9
10657011
Transplantation. 2003 May 15;75(9):1556-60
12792514
Cancer Immunol Immunother. 2007 Dec;56(12):1875-83
17479266
Blood. 1997 Oct 15;90(8):2921-30
9376572
Blood. 2001 Feb 15;97(4):835-43
11159505
Blood. 2007 Oct 15;110(8):2793-802
17638856
Hum Gene Ther. 1998 May 20;9(8):1237-50
9625264
Ann Oncol. 2000;11 Suppl 1:113-6
10707791
J Immunol. 2005 Sep 15;175(6):4137-47
16148164
Nat Clin Pract Oncol. 2006 Dec;3(12):668-81
17139318
Blood. 2007 Feb 1;109(3):1138-46
16985171
N Engl J Med. 1994 Sep 8;331(10):679-80
8052285
J Clin Oncol. 1999 Mar;17(3):825-31
10071273
Blood. 2002 Apr 1;99(7):2592-8
11895798
N Engl J Med. 1994 Apr 28;330(17):1185-91
8093146
J Infect Dis. 1974 Sep;130(3):231-9
4369787
Blood. 2002 May 1;99(9):3179-87
11964281
Int J Hematol. 2006 Jan;83(1):66-73
16443556
J Clin Invest. 2008 Jan;118(1):294-305
18060041
Am J Transplant. 2005 Mar;5(3):566-72
15707412
Blood. 2006 Nov 1;108(9):2942-9
16835376
Clin Immunol. 2001 Feb;98(2):220-8
11161978
Proc Natl Acad Sci U S A. 1999 Aug 31;96(18):10391-6
10468618
Hematology Am Soc Hematol Educ Program. 2005;:231-8
16304386
Recent Results Cancer Res. 2002;159:9-18
11785849
Cancer. 2004 May 1;100(9):1892-901
15112270
Proc Natl Acad Sci U S A. 1993 Jan 15;90(2):720-4
8421711
Blood. 2007 Oct 1;110(7):2620-30
17507664
Am J Transplant. 2007 May;7(5):1293-9
17425621
Hematology Am Soc Hematol Educ Program. 2005;:260-6
16304390
Blood. 2005 Apr 15;105(8):3051-7
15632206
Hematology Am Soc Hematol Educ Program. 2007;:204-9
18024631
Blood. 2007 Aug 15;110(4):1123-31
17468341
Br J Haematol. 2002 Sep;118(3):799-808
12181048
Nat Med. 1996 May;2(5):551-5
8616714
Annu Rev Med. 2005;56:29-44
15660500
Lancet. 1995 Jan 7;345(8941):9-13
7799740
Cancer Gene Ther. 2007 Jan;14(1):91-7
17024231
Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):6106-15
17062687
Nat Med. 2001 Oct;7(10):1118-22
11590434
Blood. 2005 Feb 15;105(4):1622-31
15507526
Blood. 2000 Feb 15;95(4):1502-5
10666232
Blood. 2003 Mar 1;101(5):1905-12
12411306
Int J Cancer. 2001 Sep 1;93(5):706-13
11477583
Transplantation. 1999 Nov 27;68(10):1517-25
10589949